From the Pump Cart to the Pocket: The Disposable Shift in Negative-Pressure Wound Therapy

1. The arc: from capital pump to registered consumable

Takeaway: NPWT is following the same path our varicose-vein report traced — a durable capital device first, then a registered single-use consumable that rides the same procedure into the recurring-revenue lane. VEMERIX is one of the few manufacturers that makes both halves.

Our companion report on the varicose-vein market documented a specific mechanism: a minimally-invasive procedure stabilizes, the capital console becomes a commodity sold once, and the value migrates to the sterile single-use item consumed in every case — the fiber, the kit, the blade. The console is the razor; the consumable is the blade; the blade is where the annuity lives.

Negative-pressure wound therapy is built for the same physics. The therapy applies controlled sub-atmospheric pressure to a sealed wound to remove exudate, reduce edema, and promote granulation. For two decades it was delivered almost exclusively by a durable, canister-based electric pump — a rented or capital console with tubing, alarms, and a separate foam-and-canister supply chain. That durable system is the razor. Then a second form factor arrived: a compact, often canister-free, single-use device built around a disposable dressing kit, registered as its own device category and sold per application. That is the blade.

The thesis of this report is that the blade is winning share, on a demand base too large and too structural to reverse — and that the shift is now visible in five independent public datasets: US Medicare procedure volumes, third-party market forecasts, global trade flows, the US FDA device record, and the US patent estate. We keep two halves of the argument distinct: integrated analysis we computed ourselves from public databases (attributed as "<Publisher> — VEMERIX/Medison analysis"), and facts lifted from named third-party publications (cited directly).

VEMERIX (Weihai Medison) is credible on this shift for a structural reason we return to at the end: it manufactures both halves of the razor-and-blade — an NMPA-registered Class II Medical Vacuum NPWT Pump and a Class II Disposable NPWT Drainage Dressing Kit — within a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. We hold that positioning to the implications section and let the public data carry the argument first.

2. The demand base: a vast, compounding wound economy

*Takeaway: before claiming a shift within the market, prove the prize is large and structurally growing. It is — diabetes, aging and a deepening wound-severity mix push the addressable base higher on every axis a single-use dressing kit addresses.*

Diabetes is the demand engine, and it is compounding

Start with the single largest secular driver. The International Diabetes Federation projects adults aged 20–79 living with diabetes rising from 537 million in 2021 to 643 million by 2030 and 783 million by 2045 — a 46% increase, roughly double the rate of world population growth; the IDF's 11th-edition figures already report 589 million ⁷¹¹. These are projections, not facts, and we treat them as such — but the direction is corroborated across editions and is the upstream cause of the wound economy.

Diabetes matters here because it manufactures wounds. Global diabetic-foot-ulcer (DFU) prevalence among people with diabetes is about 6.3%, with marked regional variation — 13.0% in North America, 7.2% in Africa, 5.5% in Asia, 5.1% in Europe — so the burden scales with both diabetes prevalence and regional risk ¹⁰. Roughly 18.6 million people with diabetes develop a foot ulcer every year worldwide, and DFU recurrence runs near 40% at one year — a chronic, repeat-treatment population, not a one-and-done one ¹⁰.

Aging stacks on top. The highest wound prevalence sits in the oldest cohorts, and the US population aged 85 and over — the segment with the greatest wound burden — is projected to roughly double, from 6.5 million in 2022 to 13.7 million by 2040 (+111%) ¹². Obesity compounds both, raising surgical-wound and chronic-wound risk across the working-age and elderly populations alike. Aging plus diabetes plus obesity is, in effect, a demand-compounding machine for advanced wound care.

Debridement: a brand-agnostic proxy for realized US wound volume

Projections describe the future; debridement describes the present. Surgical debridement (the removal of devitalized tissue) is the brand-agnostic procedure that precedes and accompanies advanced wound management, so its volume is a clean proxy for how many serious wounds the US system is actually treating. Our analysis of US Medicare Part B shows debridement services rose from 2,137,048 in 2013 to 3,708,207 in 2024 — a 73.5% increase, an additional 1.57 million procedures a year, at a 5.1% CAGR (and a steeper 8.2% CAGR through the pre-COVID 2013–2019 window) ¹. Allowed payments grew from $151.4M to $269.8M (+78%), and submitted charges crossed $1 billion in 2021 ¹.

The mix is as telling as the total. Decomposing debridement by depth, the deeper and larger-surface-area codes grew fastest: subcutaneous debridement (HCPCS 11042) rose 40.7%, muscle/fascia (11043) 123.6%, bone (11044) 71.9%, and the add-on "additional surface area" codes climbed even faster — 11045 up 151.7%, 11046 up 169.4%, and additional-bone 11047 up 273.9% (26,057 → 97,435 services) ¹. Wounds are getting deeper and wider — precisely the larger, deeper, exudative wounds that NPWT is indicated for. The workhorse code alone (11042) ran roughly 2.04 million services across about 481,000 patients and 44,000 distinct providers in 2024 — a broad, decentralized treatment base, not a handful of referral centers ¹.

About 1 in 6 Medicare beneficiaries now carries a chronic wound

Peer-reviewed burden studies put a denominator on the prize. In 2014, an estimated 8.2 million Medicare beneficiaries (14.5%) had at least one wound, at an annual cost bracketed between $28.1 billion and $96.8 billion, with surgical wounds ($11.7–38.3B) and diabetic-foot ulcers ($6.2–18.7B) the most expensive categories, and per-wound burden concentrating in the oldest patients (around 20% prevalence at 75+) ⁸. By 2019 prevalence had risen to 16.4% — about 10.5 million beneficiaries, roughly 1 in 6, an increase of 2.3 million in five years — with the fastest growth in the under-65 disabled cohort ⁶. A 2025 compendium confirms the trajectory and puts global wound-care expenditure at about $148.65 billion in 2022 ⁹.

The care setting is migrating out of the hospital — toward the channels a disposable serves

The single most thesis-relevant burden finding is not the level of spend but where it sits. Even as total Medicare wound spend fell about 20% from 2014 to 2019 ($29.7B → $22.5B), the site-of-care mix flipped hard: hospital-outpatient spend collapsed from $10.5B to $2.5B, while physician-office spend rose ($3.0B → $4.1B), durable medical equipment more than doubled ($0.3B → $0.7B), and care continued shifting toward office, DME and home settings ⁶. Care and dollars are moving out of the hospital and into exactly the ambulatory, office, DME and home channels that a registered single-use consumable is built to serve — a structural tailwind we return to in Section 5.

The global picture rhymes. Venous leg ulcers account for 70–80% of lower-extremity ulcers, with roughly 5.8 million prevalent cases across seven developed countries; UK real-world data show venous ulcers up 101%, DFU up 93%, and arterial ulcers up 244% across 2012/13–2017/18 ¹³. Every axis — diabetic, venous, surgical, age-driven — points the same way: a deepening, decentralizing, repeat-treatment wound economy.

3. The proof of the shift: US Medicare's high-fidelity window

Takeaway: this is the spine of the report. In US Medicare fee-for-service, single-use NPWT's share of application services rose every year from 0% to 21.1%, durable-pump volume peaked in 2019 and fell, and the patient count on single-use grew about 8.4x — a textbook substitution signature no competitor has published.

This section is our own analysis of CMS Medicare Physician & Other Practitioners data, CY2013–2024, national, for the four NPWT application/management codes: durable-pump NPWT (CPT 97605/97606) and disposable single-use NPWT (CPT 97607/97608) ¹. One scope limit up front, and it matters: CMS covers Medicare fee-for-service only — a predominantly elderly and disabled population. It excludes Medicare Advantage (about half of all Medicare enrollment by 2024), Medicaid, commercial payers, the VA and cash-pay, and so under-represents the younger diabetic and trauma NPWT population. Read this as a directional, high-fidelity window into the US shift, not the US total.

The share curve: 0% to 21.1%, rising every single year

Disposable NPWT did not exist in Medicare claims before 2015 — the codes first appear in CY2015, at 1,640 services for 948 patients. From there, the disposable share of all NPWT application services climbed 0% (2013–14) → 2.6% (2015) → 9.4% (2019) → 21.1% (2024), rising in every single year and accelerating after 2020 ¹. This is the mirror image of the surgery-to-minimally-invasive curve in our varicose-vein report: pump cart to pocket.

Substitution, not just growth

A rising share could in principle come from a growing pie. It does not. Disposable NPWT services grew from 1,640 (2015) to 14,176 (2024) — 8.6x, a 27.1% CAGR — while durable-pump NPWT services peaked at 70,082 in 2019 and fell to 53,045 by 2024, down 24.3% from peak ¹. Crucially, total NPWT application volume is flat-to-down: 57,287 services in 2013, a 2019 peak of 77,364, and 67,221 in 2024 ¹. Because the total is not expanding, single-use gains come substantially at the expense of the durable installed base — the defining signature of displacement, not category growth.

The patient curve confirms it

Volumes can be inflated by per-patient frequency, so we check beneficiaries directly. Patients treated with single-use NPWT rose from 948 (2015) to 7,994 (2024) — roughly 8.4x — while durable-pump beneficiaries fell from a 2019 peak of 40,663 to 30,145 in 2024, down 25.9% ¹. More patients on the disposable, fewer on the durable: the substitution is in bodies, not just billing lines. (Beneficiaries are reported by code group, not summed, because a patient treated with both forms in a year would otherwise double-count.)

Value migration — with the caveat almost everyone gets wrong

Now the dollars, and the load-bearing caveat. The disposable share of NPWT Part B payment rose from 2.6% (2015) to 60.3% (2024) — even though disposable is only about 21% of services ¹. Read naively, that looks like the disposable already owns the money. It does not, and the gap is the most-misreported number in this category.

The dollar crossover is amplified by a 2020 CMS payment-policy change, not a price spike. From CY2020, Medicare folded the single-use device cost into the office (non-facility) payment for codes 97607/97608. The office per-service rate jumped from about $37 (2019) to about $219 (2020) and roughly $258 (2024) — a six-to-seven-fold step in a single year — while the facility rate stayed flat (about $16–21, with the device supplied separately) and durable office rates were stable throughout (about $30–41) ¹¹⁴. Disposable Part B dollars duly leapt from $171K (2019) to $497K (2020) to $1.03M (2021): real volume growth plus a one-time bundling step layered on top ¹.

A second caveat travels with these dollars. These four codes pay only the clinician for applying and managing the dressing. For durable NPWT, the pump itself is a separately billed DME rental and the foam and canisters are separate DME supplies — none of which appear in this dataset, and one of which (a separate disposable NPWT device code) Medicare's own coverage policy treats as non-covered DME ¹⁵¹⁶. So the true durable "system" spend is far larger than the application line and lives off-file. The honest reading: the volume and beneficiary curves are the clean substitution signal; the dollar series must always carry the bundling caveat. Total NPWT Part B payment across these codes rose from $1.34M (2013) to $2.93M (2024) — context, not the system economics ¹.

4. The market's forward view: every forecaster says single-use is the fastest lane

Takeaway: move from realized US shift to global forward consensus. Analysts disagree on the market's absolute size by a factor of three — but where a single firm segments by product, single-use out-grows the overall market every time, recurring consumables are already the revenue majority, and a second growth vector (connected/digital NPWT) is now stacking on the first.

The fan: a range, never a single number

Across the major publishers, the global NPWT device market clusters at roughly USD 2.6–3.5 billion today — MarketsandMarkets at $2.59B (2024), Precedence Research at $2.87B (2025), Fortune Business Insights at $3.00B (2025), IMARC at $3.04B (2025), Mordor Intelligence at $3.16B (2026) — growing to about USD 3.8–5.8 billion by the early-to-mid 2030s at a blended ~5%–7.6% CAGR ^17181920221. These are third-party forecasts, not facts, and the absolute figures diverge because each firm defines the market differently (devices only versus devices-plus-consumables versus all care settings). One estimate sits well above the cluster on a broader market definition — Future Market Insights at $7.08B (2025) — and we flag it as an outlier rather than blend it in ²³. The value here is the convergence on direction and growth band, not any single point.

The wedge: single-use is the fastest sub-segment, in the same reports

Here is the finding that survives the definitional noise. Every publisher that segments by product names single-use/disposable as the fastest-growing slice, at roughly 7.8%–10.4% CAGR. The cleanest comparisons are apples-to-apples within one report: Mordor Intelligence puts single-use at 9.62% versus 6.17% for the overall market (~1.6x); Dataintelo at 10.4% versus 7.8% (~1.3x); and Data Bridge shows Asia-Pacific disposable NPWT at 10.4% against 5.21% for the regional market ²³²⁴. The ordering is robust even though the absolute single-use sizing is the least reliable cell in the whole category — Future Market Insights pegs single-use near $287.5M, The Insight Partners around $684M (2025) rising to about $1.40B by 2034 at 8.24% CAGR, and Strategic Market Research at $1.34B for a comparable period: a pure definition gap ²³⁵⁴. Lean on the CAGR and the ranking, not the dollar level.

Recurring consumables are already the revenue majority

The razor-and-blade structure shows up directly in revenue composition. Dataintelo's 2025 split puts accessories/consumables at 41.6%, conventional/durable at 38.2%, and single-use at 20.2% of category revenue — with the single-use sub-segment growing at 10.4% versus 6.8% for conventional ³. Mordor still has reusable/durable pumps at 66.56% of 2025 revenue, with single-use near a third and climbing at 9.62% ². The two firms disagree on the exact split — treat it as unsettled — but both show the recurring consumable/accessory pool as the larger or faster-growing half. The blade, not the razor, is the annuity.

The capital economics: an expensive razor, a cheap recurring blade

The cost ladder makes the asymmetry concrete for procurement. Third-party analysis puts a conventional durable console at roughly USD 20,000–35,000 in capital cost, and a portable unit at about USD 1,500–5,000 ³. On a per-day basis, analysts describe NPWT cost falling from roughly $2,000 for inpatient durable therapy toward about $200 for portable single-use — a care-cost argument that pulls volume toward the disposable form factor ². The single-use kit carries no separate capital console and lands at a low recurring per-application price (UK device cost referenced around £147 per application in HTA modelling) ³⁹. Industry analysis also notes that durable systems often use proprietary pump-dressing connectors, so third-party dressings will not fit a given pump head — a structural source of consumable lock-in that makes the recurring blade defensible ².

Geography, segments and the fast lanes

North America is consistently the largest region (about 39%–40% share; Fortune 39.89%, Precedence ~39%), with US NPWT sized near $0.89B (2025) and Asia-Pacific repeatedly named the fastest-growing region — though we present APAC-fastest as qualitative consensus, since at least one publisher (Data Bridge) shows North America growing faster than APAC, so it is not a hard CAGR claim ^1918212224. Within the category, two fast lanes matter to an export portfolio: burns are flagged as the single fastest-growing wound-type segment (~8.45% CAGR, driven by military and humanitarian first-line protocols) — squarely inside a kit indicated for second-degree burns — and ambulatory surgical centers (ASCs) are the prime single-use adopters, because a sterile, single-patient kit eliminates the reprocessing, sterilization and cross-contamination overhead of shared durable hardware ². Home care points the same way: disposables were reported as more than 35% of new home-care NPWT installs in 2025 ²¹. For framing, the all-in wound-care market is sized at $20.97B (2024) rising to $30.48B (2030) ²⁷.

The forward frontier: a second vector stacking on the disposable shift

The disposable shift is the established vector. A second one is forming on top of it: smart, connected NPWT with onboard sensors, app-based controls and remote patient monitoring (RPM). Analysts put smart-connected devices at roughly 18% of 2025 product launches and name portable NPWT the fastest technology sub-segment (~8.46% CAGR) ²¹; MarketsandMarkets dates the next inflection to 2027–2028, as "smart, connected NPWT integrating digital health ecosystems" matures ¹⁷; and US Medicare is reported to have updated reimbursement in April 2025 to bring remote patient monitoring within NPWT coverage — a payment signal that usually precedes adoption ²⁶. The honest read for an export manufacturer: the two vectors are complementary, not competing. The cost-driven disposable shift is happening now, across the whole price-sensitive global base; the connected layer is an emerging premium tier, gated by reimbursement and regulatory pathways that differ by market. A registered, cost-competitive mechanical single-use kit is the volume play today; connectivity is a roadmap question, not a present-day requirement, and we make no claim that any specific VEMERIX device carries sensor, app or RPM features.

The consumable trade pool, and its commoditization signature

Trade data sizes the consumable pool the dressing kit feeds into, and reads its price direction. In UN Comtrade reported imports, the combined wound-dressing basket (HS 300510 adhesive dressings + HS 300590 gauze/bandages) grew from $35.6B (2014) to $59.3B (2024) — roughly a $59B reported global import pool, a 5.2% value CAGR ²⁸. The closest proxy basket to the NPWT dressing kit, HS 300510, grew at a 6.2% value CAGR but a 7.7% weight CAGR — meaning volume grew faster than value and the unit price fell about 1.3%/yr (from $27.34 to $23.87/kg). That falling unit price against rising volume is the commoditization signature of a razor-and-blade consumable, and the 2020 COVID year sharpened it: adhesive-dressing import weight jumped about 30% while the unit price hit a decade low of $21.48/kg — volume-led, price-suppressing, classic consumable (not capital-equipment) economics ²⁸.

Four caveats travel with the trade data and must not be dropped. The reporter and partner country fields are blank in this extract, so it supports no country, China-origin or export-share claim of any kind. The baskets are far broader than NPWT — they size the pool, not an NPWT-specific market. Summed world imports carry mirror double-counting, so treat them as an index of size and direction plus a price signal, not a precise market value. And trade flows are not end-market sales. (A far larger instrument/parts basket, HS 901890, grew from $193.0B to $348.6B over the same window — useful only as loose "the durable side is also growing" context, never as an NPWT-pump figure.) ²⁸

5. Why the shift sticks: evidence, guidelines and care economics

Takeaway: this is not a fad. Category-level clinical evidence — honestly paired with the null trials — supports NPWT where it is targeted; guideline bodies endorse single-use NPWT for the high-risk surgical and diabetic-wound segments driving the shift; and the care economics reward a canister-free disposable.

A discipline first: we cite all clinical and HTA evidence at the category level — for NPWT and single-use NPWT as classes of device — never as a comparison of one branded product to another, and never as a clinical-superiority claim for any specific device.

The high-volume use case: single-use NPWT on closed surgical incisions

The largest near-term use case for single-use NPWT is prophylaxis on closed surgical incisions in high-risk patients. The category-level evidence is favorable. A 2022 Cochrane review of NPWT on incisions healing by primary closure found a surgical-site-infection (SSI) relative risk of 0.73 (95% CI 0.63–0.85) across 44 RCTs and 11,403 participants (moderate certainty) ²⁹. A meta-analysis focused on single-use NPWT on closed incisions reported an SSI odds ratio of 0.37 (0.28–0.50) — a 63% reduction, number-needed-to-treat about 20 ³⁰. A 2023 up-to-date synthesis graded the incisional-NPWT SSI reduction as high-certainty ³¹.

Now the honest counterweight, which actually strengthens the thesis. The largest independent, pragmatic RCTs in unselected or lower-risk populations found no benefit: the WHIST limb-fracture trial (N=1,548) reported deep SSI of 5.8% versus 6.7% (OR 0.87, p=0.52); the Tuuli obese-cesarean trial (N=1,608) reported 3.6% versus 3.4% (p=0.70); and the SUNRRISE emergency-laparotomy trial (2025) found no reduction ³²³³³⁴. The net reading is not "NPWT doesn't work" — it is that incisional single-use NPWT is a targeted prophylactic for high-SSI-risk closed incisions, and the benefit dilutes in unselected populations. Selectivity is precisely what makes a low-cost, off-the-shelf disposable the right tool: use it where the risk justifies it, on the patients the guidelines name.

Treating established wounds in the diabetes-and-aging base

For established wounds — the chronic, diabetic and post-amputation wounds the demand base manufactures — the category evidence is supportive but more cautious. Cochrane (2018) found NPWT improved diabetic-foot-ulcer healing (RR 1.40, 95% CI 1.14–1.72), shortened time-to-healing (HR 1.82, 1.27–2.60), and reduced amputation (RR 0.33, 0.15–0.70), at low certainty ³⁵. Two landmark RCTs anchor the diabetic-foot case: Armstrong & Lavery (2005) reported 56% versus 39% healed (p=0.040), and Blume (2008) reported closure of 43.2% versus 28.9% (p=0.007) with amputation of 4.1% versus 10.2% (p=0.035) ³⁶³⁷. The caveat, again kept honest: in unselected open and secondary-intention wounds, NPWT shows no clear benefit and is not cost-effective — the SWHSI-2 pragmatic trial and the related Cochrane review on secondary-intention wounds are clear on this ³⁸. Lead with targeted prophylaxis and targeted DFU/post-amputation healing, not blanket open-wound claims.

Guideline and HTA bodies have endorsed the disposable form factor

Practice has been codified, and the guidance converges on single-use NPWT for the exact segments driving the shift. The clearest is NICE MTG43 (now HTG509), the UK medical-technologies guidance on single-use NPWT for closed surgical incisions: published 9 May 2019 and re-affirmed unchanged in February 2024, it recommends single-use NPWT "should be considered as an option" for patients at high SSI risk (age, obesity, smoking, diabetes, emergency or repeat surgery). The 2024 review meta-analysis put SSI at RR 0.60 (0.47–0.77) across 20 RCTs and 7,050 patients, and the cost modelling found extra benefit at similar cost — cost-saving in higher-risk patients (a breast-reconstruction model showed about −£1,539 per patient, cost-saving in 99.94% of simulations, on a device cost around £147) ³⁹. Surrounding guidance points the same way: NICE NG192 supports considering NPWT after caesarean for BMI ≥35; NG19 supports it for diabetic-foot ulcers after surgical debridement, specifying the lowest-acquisition-cost appropriate dressing; NG37 notes it reduces dressing changes, nursing time and pain in complex fractures even where it is not "more effective"; WHO's 2018 SSI guidelines give prophylactic NPWT on closed high-risk incisions a conditional recommendation; and IWGDF (2019) supports considering it for post-operative surgical foot wounds ^4041424445.

Critically, the selectivity in this guidance is a tailwind for a cheap disposable, not a brake. NICE CG179 says not to offer NPWT routinely for pressure ulcers "unless to reduce the number of dressing changes," and IWGDF advises against it for non-surgical DFU ⁴³⁴⁵. A guideline landscape that says "use it selectively, and choose the lowest-acquisition-cost option" is a landscape that rewards an affordable, registered, off-the-shelf single-use kit.

Both halves have a role — the suitability matrix procurement actually uses

The shift to single-use is not a claim that the disposable replaces the durable everywhere. Consensus guidance frames a clean division of labor. Single-use NPWT suits closed incisions and small, shallow, lower-exudate wounds (up to roughly 13×13 cm, 2–3 cm depth, ~180 mL/week exudate), in a canister-free, peel-and-place format around 70 g, across OR, clinic, home-health, long-term-care and ambulatory settings, at lower recurring cost. Durable-pump NPWT remains the tool for large, deep, cavity and high-exudate wounds (>180 mL/week), in a 500–1,000 g format with canister, tubing and alarms, for acute care and community-with-support, at higher capital and canister-logistics cost ⁴⁷. This is a suitability matrix, not a superiority ranking — and it is exactly why a manufacturer that makes both halves can serve the whole curve.

The real value lever is care economics, not the device price

The deepest reason the shift sticks is where wound cost actually lives. In the UK, the NHS managed about 3.8 million wound patients in 2017/18 (around 7% of adults, up 71% in five years) at roughly £8.3 billion a year (£2.7B on healed wounds, £5.6B on unhealed) ¹³. The decomposition is the punchline: 81% of that cost is incurred in the community, more than 70% is clinician-visit time, and wound products themselves are only about 6% of cost ¹³. When the cost is nurse time and care contacts, the value lever is fewer dressing changes and care delivered outside the hospital — exactly what a canister-free single-use consumable enables. An NHS cost-effectiveness model put single-use NPWT savings at about £1,132 per patient, rising to roughly £7,955 in patients with BMI ≥35 ⁴⁶.

6. A mature, commoditizing Class II field: the FDA record

Takeaway: the US FDA record underwrites the Class II framing and shows the regulatory and field burden concentrates on the durable hardware — while single-use is a real, registered, growing FDA category. Read the safety data neutrally: concentration reflects installed-base exposure, not relative safety.

A Class II taxonomy, durable first and single-use second

All four NPWT product codes in the US are Class II: the durable powered suction pump (OMP, regulation 878.4780), the powered closed-incision/wound-complication-reduction device (QFC, 878.4783), and two non-powered single-use codes (OKO and QPX, both 878.4683) ⁴⁸. The sequence mirrors the razor-and-blade arc precisely: the durable pump came first, and the single-use category was created later — OKO by a De Novo classification in 2009, with QPX first appearing in 2021 ⁴⁸⁵². Durable capital device first; registered single-use consumable second.

A crowded, commoditizing clearance landscape

The clearance record reads like a mature, commoditizing field. Across the four codes there are 233 total 510(k) clearances, of which the durable pump (OMP) accounts for 212 — 91% — with OKO at 17, QFC at 3, and QPX at 1, spread across 73 distinct applicants ⁴⁹. Annual activity scaled from about 1–3 per year before 2005 to a sustained 11–21 per year in 2012–2019 (peaking at 21 in 2015), settling to 7–12 per year in the 2020s ⁴⁹. The disposable shift is visible inside the record itself: single-use-format clearances account for 32 of the 233, recurring for over a decade. A large, multi-applicant, predicate-based clearance base is the regulatory fingerprint of a commoditizing category with a long OEM and private-label tail.

The field burden sits on the durable hardware

Recalls and adverse-event reports concentrate sharply on the durable pump. The table below summarizes the four codes across the FDA's three field-safety windows.

There have been 48 NPWT recalls, 47 of them (98%) on the durable OMP pump, one on QFC, and zero on the non-powered single-use codes; 79% (38 of 48) trace to hardware causes — nonconforming material or components, device design, packaging and sterile-barrier, and labeling — peaking at 19 recall actions in 2014 ⁵⁰. The MAUDE adverse-event database holds 9,183 reports, of which 9,173 (99.9%) are on the durable OMP ⁵¹.

That 99.9% must be read neutrally, and we state the caveats up front. The durable pump is essentially the entire powered installed base, so the concentration reflects exposure, not relative safety. The event mix is dominated by device behavior rather than clinical harm: malfunctions 5,800 (63%), injuries 3,275 (36%), deaths 75 (0.8%); 96.7% were manufacturer-filed and roughly 75% (6,929) list no clinical harm ("no clinical signs," "no consequence," "no patient involvement") — the fingerprint of device-hardware field reporting, not a clinical-safety alarm ⁵¹.

A 2020 surge to 3,664 reports (with 1,427 in 2021 — together 55% of all reports ever) was a field-action wave on durable hardware, 78% malfunctions and mostly no-impact, after which reporting normalized to about 135–145 per year in 2023–25, below the 2018–19 baseline ⁵¹. The honest conclusion is narrow and defensible: the durable, powered device by construction exposes more recall and report surface than a non-powered single-use kit — a complexity and field-burden signal, not a "single-use is safer" claim.

The single-use side is a real, registered FDA category with its own special-controls pathway for non-powered NPWT, created by De Novo in 2009 and extended with a second code in 2021 ⁵²⁴⁸. Taken together — durable pump at 91% of clearances, 98% of recalls and 99.9% of adverse-event reports — the US record validates the razor-and-blade structure against the highest-fidelity regulatory window available, and underwrites a Class II-only reading of the field.

7. The IP map: a consolidated durable core, an open consumable frontier

Takeaway: the US patent estate is a dumbbell — a heavily consolidated durable-pump core at the head, and a long fragmented tail where three of four named assignees file only once. The open lane is the consumable frontier, away from the durable-pump thicket. This is landscape evidence, not a benchmark.

A method-and-noise note first, because the raw counts mislead. We pulled USPTO application records (filing years 2005–2026) on two keywords — "negative pressure wound" (4,955 raw rows) and "wound dressing" (2,647 raw rows) — for 7,602 distinct rows with zero overlap ⁵³. The raw counts overstate badly ("wound" is also the past tense of "to wind"; "dressing" also means semiconductor and salad), so a conservative title filter removes 828 off-topic rows (10.9%) and keeps about 6,774 plausibly medical filings; these are directional, never cited raw.

Two structural limits apply. Harvest gaps (2021 is missing for both terms, and several term-years are empty) are why we deliberately do not publish a filings-by-year trend and instead use the gap-insensitive cross-year applicant ranking. And the pull is US-only, so it under-represents the large international patent families (CN/EP/JP/WO) and must not be read as global competitive share ⁵³.

With those guardrails, the shape is clear. The head is consolidated: rolling assignees to current ownership, the single largest wound-care patent family holds 692 kept filings — about 19.7% of the 3,508 named filings — and the top two families together hold about 28.2%, with a single corporate estate accounting for roughly three-quarters of the leading family ⁵³. The next tiers fall off fast; the top five account for about 33.5% and the top ten about 38.3%.

The tail is fragmented: across 1,432 distinct named assignees, 1,070 — 74.7% — appear exactly once ⁵³. That single-filing tail, not the raw "no assignee" rate, is the real evidence of fragmentation: the apparent 48% "no assignee" share is largely a pre-AIA recording artifact (blank-assignee share was 81.7% before the 2012 America Invents Act disclosure rules versus 16.1% after), and about 84% of recent kept filings carry a named assignee ⁵⁴⁵³. Lifecycle data reinforce the "frontier" reading: only about 36% of kept filings (roughly 2,446) were ever granted, the rest abandoned, lapsed or in PCT storage — a speculative, low-conversion field ⁵³.

The strategic read is structural, not a competitive comparison: the durable-pump IP core is concentrated and defended, while the single-use-consumable frontier is fragmented and open — the lane in which a registered single-use dressing kit competes on cost, format and registration rather than against the durable-pump patent thicket. Independent market analysis frames the same asymmetry at the company level: the durable side is semi-consolidated (a leading vendor is put near ~20% share and the top five near ~55% in 2025), with high entry barriers, while ongoing single-use innovation keeps the consumable lane open to emerging participants ²⁵.

8. The honest objections, steelmanned

Takeaway: the strongest case names its own counter-arguments. Three objections — medical-waste/ESG pressure, reimbursement gating, and incumbent lock-in — are real restraints on the disposable thesis. Each has an honest answer, and addressing them is what separates intelligence from cheerleading.

Objection 1: single-use means more medical waste

The most obvious objection to a "single-use wins" thesis is sustainability. Disposables generate waste, and disposal regulation is tightening — analysts cite NPWT-waste disposal rules as a near-term growth drag (on the order of −0.3% to category CAGR), concentrated in the EU and in US states such as California and New York, and increasingly name eco-friendly materials and ESG performance as a competitive differentiator ²¹⁷. This is a genuine headwind, and a procurement or tender reader is right to raise it.

The honest counter is in the care economics, not in dismissing the concern. Because about 81% of wound cost is incurred in the community, more than 70% is clinician-visit time, and wound products are only ~6% of total cost ¹³, the largest environmental and economic footprint of wound care is the care pathway — visits, travel, nursing time, hospital bed-days — not the dressing itself. A form factor that reduces dressing-change frequency and shifts care out of the hospital can lower the total footprint of an episode even though the device is disposable. The waste question is real and should be designed for (material choice, take-back where mandated); it does not, on the available evidence, reverse the total-cost-of-care logic that drives the shift.

Objection 2: adoption is reimbursement-gated, and uneven across markets

A US-and-UK-centric reading would overstate how smoothly the shift travels. For a global export audience the reality is that single-use NPWT adoption is gated by national reimbursement, and coverage is fragmented. Western European cover runs country-by-country — several markets carry dedicated inpatient NPWT coverage while outpatient cover is uneven and, in England, advanced dressings are reimbursed but device cover is guidance-gated; Australia gates access through cost-effectiveness appraisal; and emerging markets run high out-of-pocket shares with uncertain single-use cover, which analysts quantify as a near-term CAGR drag concentrated in markets such as India, Brazil and South Africa ²⁶². The US, by contrast, is the most mature single-use lane and is now reported to be folding remote monitoring into NPWT coverage ²⁶.

The decision-useful implication: this is not one global play. Push the single-use kit hardest where coverage or guideline endorsement already exists, lead with the durable pump or a cost-competitive cash-pay kit where single-use is not yet reimbursed, and treat reimbursement status as a market-entry variable, not an afterthought.

Objection 3: incumbent lock-in and price compression cut both ways

The proprietary pump-dressing connector that makes the recurring blade defensible is, from a new entrant's seat, a barrier: a durable installed base, group-purchasing and tender incumbency, and pump heads that reject third-party dressings all favor the established player. The escape hatch is structural — a stand-alone single-use kit is not tethered to any incumbent pump head, so it competes on its own registration, format and cost rather than against the durable thicket. Likewise, the commoditization that opens the OEM/private-label lane also compresses margins: analysts note that generic device manufacturing can cut NPWT prices by roughly 35–50%, which is exactly what opens the consumable opportunity and exactly what disciplines pricing in it ³. Both forces are real; both point to the same strategy — compete in the open consumable lane on registration, cost and reliability, with eyes open on margin.

9. What it means for the export market — and where VEMERIX fits

Takeaway: the razor-and-blade shift in NPWT is now proven from five independent public datasets and stress-tested against its own objections. For distributors, procurement teams, OEM/private-label buyers and clinicians, the recurring single-use consumable is the strategic prize — and VEMERIX is one of the few manufacturers that registers both halves of it.

The shift is real, durable, and multi-sourced

Pull the threads together. US Medicare shows single-use NPWT rising every year to 21.1% of application services while durable volume fell 24.3% off its peak on a flat total — substitution, not just growth ¹. Independent forecasters, despite a three-fold spread in absolute sizing, unanimously name single-use the fastest sub-segment at ~7.8%–10.4% CAGR, with recurring consumables already the revenue majority ²³. Trade data sizes a ~$59B global consumable import pool with a falling unit price — the commoditization signature of a blade business ²⁸. The FDA record concentrates clearances, recalls and adverse events on the durable hardware while confirming single-use as a real, growing registered category ⁴⁹⁵⁰⁵¹. And the patent estate is a dumbbell with an open consumable frontier ⁵³. Five datasets, one direction.

What each audience should weigh

For international distributors and importers: demand is structural (diabetes, aging, obesity), decentralizing (out of hospital into office, DME and home), and tilting toward the single-use form factor. The portfolio question is not "durable or disposable" but "can my supplier serve the whole suitability curve" — closed incisions and small low-exudate wounds with a single-use kit, large and deep wounds with a durable pump — under one registration relationship. And it is region-specific: lead with the kit where single-use is reimbursed or guideline-endorsed, and with the pump or a cash-pay kit where it is not ²⁶.

For hospital and clinic procurement and tender teams: the care-economics evidence is the lever. With 81% of wound cost in the community and over 70% of it clinician time, the line items that move budgets are dressing-change frequency, nurse-visit time, and canister logistics — not the unit price of the device ¹³. A canister-free single-use consumable, used selectively on the high-SSI-risk and post-debridement patients the guidelines name, is the form factor those economics reward ³⁹. For ambulatory surgical centers specifically, the cleanest rationale is operational: a sterile, single-patient kit comes in, leaves with the patient, and removes the reprocessing, sterilization and cross-contamination overhead of shared durable hardware ².

For OEM and private-label buyers: the FDA clearance base — 233 clearances across 73 applicants, predicate-based, Class II — is the signature of a commoditizing category with a long private-label tail, and the consumable frontier of the patent landscape is fragmented and open ⁴⁹⁵³. The recurring dressing kit is where unit economics and volume concentrate — with the honest proviso that the same commoditization compresses price, so reliability, registration and cost discipline win the lane ³.

For wound-care clinicians: the category-level evidence supports targeted use — single-use NPWT on high-risk closed incisions (SSI RR around 0.60 in the NICE review), NPWT on diabetic-foot ulcers after debridement — while the null trials in unselected populations argue for selectivity, not blanket adoption ³⁹³⁵. The disposable form factor lowers the threshold to apply the therapy where it is indicated.

Where VEMERIX fits

VEMERIX (Weihai Medison) is positioned at both ends of the razor-and-blade, which is why it can speak to the whole shift rather than one side of it. It manufactures a Class II Medical Vacuum NPWT Pump (NMPA Lu Mech Reg. 20182140303) — adjustable −50 to −450 mmHg in 10 mmHg steps, 1.5–8.0 L/min suction, continuous and intermittent modes, under 45 dB, running on AC/DC, battery and 12 V vehicle power, rated beyond 10,000 hours — the durable half suited to the large, deep, high-exudate wounds the suitability matrix assigns to a pump. And it manufactures a Class II Disposable NPWT Drainage Dressing Kit built around its own proprietary S.O.M.T side-suction multi-chamber drainage cup, with PVA/PU foam (Type I/II), a biological semi-permeable membrane, a 400–600 µm pore structure and a tee connector, indicated across acute, chronic and traumatic wounds, venous and diabetic ulcers, second-degree burns, and grafts and flaps — the recurring single-use half this report identifies as the strategic prize. The S.O.M.T cup is VEMERIX's own engineering design; we describe it as such, not as clinically superior to any other device.

On the forward frontier, the positioning is deliberately honest: VEMERIX competes today as a registered, cost-competitive mechanical single-use and durable manufacturer — the volume play across the whole price-sensitive global base — while the connected/RPM layer is an emerging premium tier we do not claim for any specific device. That is the right place to be while the first vector (cost-driven disposable substitution) is the one actually moving share, and the second (digital/connected) is still reimbursement- and pathway-gated market by market.

The point is the structure, not a superlative. The disposable shift in NPWT is the same arc, on a larger and faster-compounding demand base, that our varicose-vein report documented in endovenous ablation. A manufacturer that registers both the pump and the dressing kit — within a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care — is aligned with where the public data say the value is going: minimally-invasive wound therapy, growing globally, consumed one sterile kit at a time.

Conclusion

The substitution is real and multi-sourced. Single-use NPWT rose from 0% to 21.1% of US Medicare NPWT application services in a decade, gaining share every year, while durable-pump volume fell 24.3% off its 2019 peak on a flat total — and the same razor-and-blade direction shows up independently in market forecasts, trade flows, the FDA record and the patent estate. This is not a forecast; it is a realized shift in the highest-fidelity window we have.

The demand base makes it durable. About 1 in 6 Medicare beneficiaries carries a chronic wound, debridement volume rose 73.5% in a decade with the deepest wounds growing fastest, and diabetes is projected toward 783 million adults by 2045. Care is migrating out of the hospital into the office, DME and home channels a disposable serves. The drivers are structural, not cyclical.

The value is in the consumable, and the evidence says use it selectively. Recurring consumables are already the revenue majority and the fastest-growing slice; the capital economics (a $20,000–35,000 console versus a low-cost recurring kit) and the care economics (81% of wound cost in the community, products only ~6%) reward a canister-free disposable; and the clinical and HTA evidence supports targeted use on high-risk closed incisions and post-debridement diabetic-foot wounds — honestly, the benefit dilutes in unselected populations, which is a reason to target, not to abstain.

The honest caveats and objections are part of the case. The dollar crossover is partly a 2020 CMS bundling step, not a price spike; the CMS window is Medicare fee-for-service only; market sizes are third-party estimates presented as a range; the trade data carries no country dimension; adoption is reimbursement-gated and uneven by region; the medical-waste/ESG objection is real and answered through total-cost-of-care, not dismissed; and all clinical evidence is cited at category level. A second growth vector — connected/digital NPWT — is forming on top of the disposable shift, and we position VEMERIX honestly within it. The thesis survives every one of those disciplines: a registered single-use consumable is displacing a durable capital device, on a demand base too large to reverse.